Dogwood Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $41.30M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | $-0.15 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 18, 2026 | Before market open | – | $-0.26 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-8.20 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | $-1.99 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | $-8.45 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | During market hours | – | $-6.29 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-2.05 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.05 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.07 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | Before market open | – | $-0.06 | – |
Press releases
Announcements Dogwood Therapeutics filed with the SEC
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
CEO Letter to Dogwood Therapeutics Shareholders: First Quarter 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CEO Letter to Dogwood Therapeutics Shareholders: The Year in Review, The Year Ahead
Regulation FD disclosure · EX-99.1 to Form 8-K
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Deep Commitment to Advancing First-in-Class New Therapeutic Treatments for
Regulation FD disclosure · EX-99.1 to Form 8-K
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Deepening our Commitment to Patients
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
Other events · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Virios Therapeutics, Inc. and Wex
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Virios Therapeutics, Inc. (“Virios”) and Sealbond Limited (“Sealbond”), an indirect parent of Wex Pharmaceuticals, Inc. (“Wex”), have entered into a definitive share exchange agreement pursuant to which the companies will combine in an all-stock transaction (the “Combination”).
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
Material agreement · Other events · EX-99.1 to Form 8-K
First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
We would like to thank you for your support this past year and provide you with a corporate progress report as we enter 2024:
Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
We wanted to provide you with a succinct corporate progress report as we exit the third quarter of 2023, which can be summarized as follows:
Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
Other events · EX-99.1 to Form 8-K
Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
Results of operations · Other events · EX-99.1 to Form 8-K
Sent via Electronic Delivery to : [email protected]
Other events · EX-99.1 to Form 8-K
First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Virios Therapeutics Announces Fourth Quarter and Full Year 2022
Results of operations · EX-99.1 to Form 8-K
We announced the results of these additional analyses on November 14 th which can be summarized as follows:
Regulation FD disclosure · EX-99.1 to Form 8-K
Cause of Fibromyalgia, Long COVID
Regulation FD disclosure · EX-99.1 to Form 8-K
Virios Therapeutics Announces Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Virios Therapeutics, Inc. Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Virios Therapeutics, Inc. Announces Pricing of Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K